1-5 of 5
Sotirios Stergiopoulos
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 1664: Discovery of a novel and potent TACC3 protein-protein interaction inhibitor targeting highly aggressive cancers

Ozgur Sahin, Erden Banoglu, Chaemin Lim, Burcu Caliskan, Emmanuel Cruz, Sotirios Stergiopoulos, Sridhar Vempati
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 1664.
https://doi.org/10.1158/1538-7445.AM2023-1664
Published: 04 April 2023
View article titled, Abstract 1664: Discovery of a novel and potent TACC3 protein-protein interaction inhibitor targeting highly aggressive cancers
Journal Articles

Abstract A72: Phase 1 study of nivolumab (nivo) + nab-paclitaxel (nab-P) ± gemcitabine (G) in pancreatic cancer (PC): safety evaluation of patients treated with nivo + nab-P in arm A

Howard S. Hochster, Zev A. Wainberg, Martin Gutierrez, David Waterhouse, E Gabriela Chiorean, Ben George, Amy Ko, Victoria Manax, Sotirios Stergiopoulos, Peter O'Dwyer
Journal: Cancer Research
Cancer Res (2016) 76 (24_Supplement): A72.
https://doi.org/10.1158/1538-7445.PANCA16-A72
Published: 14 December 2016
View article titled, Abstract A72: Phase 1 study of nivolumab (nivo) + nab-paclitaxel (nab-P) ± gemcitabine (G) in pancreatic cancer (PC): safety evaluation of patients treated with nivo + nab-P in arm A
Journal Articles

Abstract CT141: Phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) + carboplatin (C) in advanced NSCLC: safety and efficacy results

David M. Waterhouse, Ben George, Martin Gutierrez, Greg A. Otterson, Amy Ko, Teng Jin Ong, Sotirios Stergiopoulos, Nataliya Trunova, Karen Kelly
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT141.
https://doi.org/10.1158/1538-7445.AM2016-CT141
Published: 15 July 2016
View article titled, Abstract CT141: Phase I study of nivolumab (nivo) + <em>nab</em>-paclitaxel (<em>nab</em>-P) + carboplatin (C) in advanced NSCLC: safety and efficacy results
Journal Articles

Down-Regulation of Regulatory Subunit Type 1A of Protein Kinase A Leads to Endocrine and Other Tumors

Kurt J. Griffin, Lawrence S. Kirschner, Ludmila Matyakhina, Sotirios Stergiopoulos, Audrey Robinson-White, Sara Lenherr, Frank D. Weinberg, Edward Claflin, Elise Meoli, Yoon S. Cho-Chung, Constantine A. Stratakis
Journal: Cancer Research
Cancer Res (2004) 64 (24): 8811–8815.
https://doi.org/10.1158/0008-5472.CAN-04-3620
Published: 16 December 2004
View article titled, Down-Regulation of Regulatory Subunit Type 1A of Protein Kinase A Leads to Endocrine and Other Tumors
Open the PDF for Down-Regulation of Regulatory Subunit Type 1A of Protein Kinase A Leads to Endocrine and Other Tumors in another window
Includes: Supplementary data
Journal Articles

Molecular and Functional Analysis of PRKAR1A and its Locus (17q22–24) in Sporadic Adrenocortical Tumors: 17q Losses, Somatic Mutations, and Protein Kinase A Expression and Activity

Jerome Bertherat, Lionel Groussin, Fabiano Sandrini, Ludmila Matyakhina, Thalia Bei, Sotirios Stergiopoulos, Theocharis Papageorgiou, Isabelle Bourdeau, Lawrence S. Kirschner, Caroline Vincent-Dejean, Karine Perlemoine, Christine Gicquel, Xavier Bertagna, Constantine A. Stratakis
Journal: Cancer Research
Cancer Res (2003) 63 (17): 5308–5319.
Published: 18 September 2003
View article titled, Molecular and Functional Analysis of <em>PRKAR1A</em> and its Locus (17q22–24) in Sporadic Adrenocortical Tumors: <subtitle>17q Losses, Somatic Mutations, and Protein Kinase A Expression and Activity</subtitle>
Open the PDF for Molecular and Functional Analysis of <em>PRKAR1A</em> and its Locus (17q22–24) in Sporadic Adrenocortical Tumors: <subtitle>17q Losses, Somatic Mutations, and Protein Kinase A Expression and Activity</subtitle> in another window